Kineta EBITDA Margin 2014-2024 | KANT
Current and historical EBITDA (Earnings Before Interest, Taxes, Depreciation and Amortization) margin for Kineta (KANT) over the last 10 years. The current EBITDA margin for Kineta as of June 30, 2024 is .
| Kineta EBITDA Margin Historical Data |
| Date |
TTM Revenue |
TTM EBITDA |
EBITDA Margin |
| 2023-12-31 |
$0.01B |
$-0.02B |
-300.00% |
| 2023-06-30 |
$0.01B |
$-0.04B |
-760.00% |
| 2023-03-31 |
$0.00B |
$-0.04B |
-4200.00% |
| 2022-12-31 |
$0.00B |
$-0.04B |
-4100.00% |
| 2022-09-30 |
$0.00B |
$0.00B |
100.00% |
| 2022-06-30 |
$0.01B |
$-0.00B |
-40.00% |
| 2022-03-31 |
$0.01B |
$-0.01B |
-116.67% |
| 2021-12-31 |
$0.01B |
$-0.01B |
-110.00% |
| 2021-09-30 |
$0.01B |
$-0.06B |
-533.33% |
| 2021-06-30 |
$0.01B |
$-0.06B |
-469.23% |
| 2019-03-31 |
$0.01B |
$-0.07B |
-942.86% |
| 2018-09-30 |
$0.01B |
$-0.06B |
-1140.00% |
| 2018-06-30 |
$0.01B |
$-0.05B |
-883.33% |
| 2018-03-31 |
$0.01B |
$-0.06B |
-916.67% |
| 2017-12-31 |
$0.01B |
$-0.06B |
-983.33% |
| 2017-09-30 |
$0.01B |
$-0.06B |
-687.50% |
| 2017-06-30 |
$0.01B |
$-0.05B |
-650.00% |
| 2017-03-31 |
$0.01B |
$-0.04B |
-550.00% |
| 2016-12-31 |
$0.01B |
$-0.04B |
-462.50% |
| 2016-09-30 |
$0.01B |
$-0.03B |
-680.00% |
| 2016-06-30 |
$0.00B |
$-0.03B |
-750.00% |
| 2016-03-31 |
$0.00B |
$-0.03B |
-700.00% |
| 2015-12-31 |
$0.00B |
$-0.03B |
-625.00% |
| Sector |
Industry |
Market Cap |
Revenue |
| Medical |
MED-BIOMED/GENE |
$0.000B |
$0.005B |
|
Kineta, Inc. is a clinical-stage biotechnology company. It develops next-generation immunotherapies that address the major challenges with current cancer therapy. The company's lead asset is KVA12123, a novel VISTA blocking immunotherapy. Kineta merged with Yumanity Therapeutics, Inc., and is based in Seattle.
|
